Juno Therapeutics acquired the license to Eli Lilly and Co.'s gamma secretase inhibitor LY3039478, which is in early-stage studies for treatment of advanced or metastatic solid tumors, and Phase I/II trials for T cell acute lymphoblastic leukemia and T cell lymphoblastic lymphoma indications. In two other deals, Juno gained from OncoTracker and Fred Hutchinson Cancer Research Center exclusive rights to intellectual property "within the field of combinations" of gamma secretase inhibitors and BCMA-directed engineered T cells.
Juno enters into licensing deals on multiple myeloma program
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.